Ruconest conestat alfa regulatory update

EMA’s CHMP recommended expanding the label of Ruconest conestat alfa from Pharming to treat acute angioedema attacks to include adolescents with hereditary angioedema (HAE) due to complement 1 (C1) esterase inhibitor deficiency. The recombinant human C1 esterase inhibitor is approved in adults. ...